



Consortia Biomarkers and Evolving Data Analytics: Delivery of New Tools for Drug Trials

Chairs:

William Potter, MD, PhD

Anzalee Khan, PhD

Disclosures

Anzalee Khan, PhD

- Employee of: Nathan S. Kline Institute for Psychiatric Research and Manhattan
- Psychiatric Center Consultant to: Valis Biosciences and WCG Copernicus

Bill Potter, MD, PhD

- Stock and/or Equity in Merck, Praxis BioResearch and DeuteR
- Consultant to: Neurocrine, Theravance, Boston Pharmaceuticals, DSMB for Agenebio and Regenacy, Advisory Board for Karuna, Neurocrine, Empyrean, Otsuka



Speakers

Cheryl Corcoran, MD

Jeff Dage, PhD

Michael Detke, MD, PhD

Kevin Krudys, PhD

Valentina Mantua, MD, PhD


Ken Marek, MD

Anzalee Khan, PhD

Bill Potter, MD, PhD



BIOMARKER DATA REPOSITORIES IN CNS TRIALS





GOALS

This symposium will highlight how far relevant efforts have progressed, and the importance of integrating a range of biomarker technologies into clinical efficacy trials.

Jeff Dage <i>Indiana University</i>	Leveraging Data and Analytic Approaches in ADNI for Enhanced Clinical Trial Participant Selection and Characterization
Cheryl Corcoran <i>Mt. Sinai School of Medicine</i>	Accelerating Medicines Partnership (AMP) - Schizophrenia: Advancing Collaborative Research for Improved Treatments
Ken Marek <i>Michael J. Fox Foundation for Parkinson's Research</i>	Advancing Parkinson's Disease Research: The AMP-PD Program by the Michael J. Fox Foundation
Michael Detke <i>Lighthouse Pharma, University of Indiana, Neumarker</i>	Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care: Data Repository